Apella Capital
CLDX icon

Apella Capital’s Celldex Therapeutics CLDX Stock Holding History

Apella Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$811K Hold
26,658
– – 0.01% 426
2026
Q2 		$1.06M Buy
26,658
+9,634
+57% +$311K 0.02% 363
2026
Q1 		$588K Hold
17,024
– – 0.01% 431
2025
Q4 		$462K Hold
17,024
– – 0.01% 371
2025
Q3 		$452K Buy
17,024
+24
+0.1% +$556 0.01% 340
2025
Q2 		$357K Hold
17,000
– – 0.01% 328
2025
Q1 		$279K Buy
+17,000
New +$380K 0.01% 316

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
Overbrook Management Corp
Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Apella Capital's CLDX Position: Q3 2026 in Review

Apella Capital held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 26,658 shares worth $811K. The position accounts for 0.01% of the portfolio, ranked #426.

Apella Capital first reported a position in CLDX in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.06M in Q2 2026. 22 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Apella Capital held 26,658 shares of Celldex Therapeutics worth $811K as of Q3 2026.
  • Apella Capital left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up 0.01% of Apella Capital's portfolio in Q3 2026, its #426 holding.
  • Apella Capital first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Apella Capital's Celldex Therapeutics position peaked at $1.06M in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Apella Capital's 13F filing for Q3 2026, filed 8 Oct 2026.